Literature DB >> 28434129

Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.

Osmany Larralde1, Juraj Petrik2.   

Abstract

Hepatitis E is an emerging zoonotic infection of increasing public health threat for the UK, especially for immunosuppressed individuals. A human recombinant vaccine has been licensed only in China and is not clear whether it protects against hepatitis E virus (HEV) genotype 3, the most prevalent in Europe. The aim of this study was to use phage display technology as a tool to identify peptides that mimic epitopes of HEV capsid (mimotopes). We identified putative linear and conformational mimotopes using sera from Scottish blood donors that have the immunological imprint of past HEV infection. Four mimotopes did not have homology with the primary sequence of HEV ORF2 capsid but competed effectively with a commercial HEV antigen for binding to anti-HEV reference serum. When the reactivity profile of each mimotope was compared with Wantai HEV-IgG ELISA, the most sensitive HEV immunoassay, mimotopes showed 95.2-100% sensitivity while the specificity ranged from 81.5 to 95.8%. PepSurf algorithm was used to map affinity-selected peptides onto the ORF2 crystal structure of HEV genotype 3, which predicted that these four mimototopes are clustered in the P domain of ORF2 capsid, near conformational epitopes of anti-HEV neutralising monoclonal antibodies. These HEV mimotopes may have potential applications in the design of structural vaccines and the development of new diagnostic tests.

Entities:  

Keywords:  Conformational epitopes; Diagnostic; HEV ORF2 capsid; Mimotopes; Phage display; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28434129     DOI: 10.1007/s00430-017-0507-0

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  58 in total

1.  Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus.

Authors:  Morag Ferguson; Dawn Walker; Eric Mast; Howard Fields
Journal:  Biologicals       Date:  2002-03       Impact factor: 1.856

2.  A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries.

Authors:  Richard Bendall; Vic Ellis; Samreen Ijaz; Rachel Ali; Harry Dalton
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

3.  Rapid and efficient identification of epitopes/mimotopes from random peptide libraries.

Authors:  Xiaoli Yu; Gregory P Owens; Donald H Gilden
Journal:  J Immunol Methods       Date:  2006-09-15       Impact factor: 2.303

4.  Seroprevalence study in forestry workers from eastern Germany using novel genotype 3- and rat hepatitis E virus-specific immunoglobulin G ELISAs.

Authors:  Paul Dremsek; Jürgen J Wenzel; Reimar Johne; Mario Ziller; Jörg Hofmann; Martin H Groschup; Sandra Werdermann; Ulrich Mohn; Silvia Dorn; Manfred Motz; Marc Mertens; Wolfgang Jilg; Rainer G Ulrich
Journal:  Med Microbiol Immunol       Date:  2011-12-18       Impact factor: 3.402

5.  Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003.

Authors:  Licel de los Angeles Rodríguez Lay; Ariel Quintana; María Caridad Montalvo Villalba; Gilda Lemos; Marité Bello Corredor; Aidonis Gutiérrez Moreno; Pablo Aguiar Prieto; María G Guzmán; David Anderson
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327

6.  Hepatitis E virus in Scottish blood donors.

Authors:  A Cleland; L Smith; C Crossan; O Blatchford; H R Dalton; L Scobie; J Petrik
Journal:  Vox Sang       Date:  2013-06-13       Impact factor: 2.144

7.  Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm.

Authors:  Itay Mayrose; Tomer Shlomi; Nimrod D Rubinstein; Jonathan M Gershoni; Eytan Ruppin; Roded Sharan; Tal Pupko
Journal:  Nucleic Acids Res       Date:  2006-12-06       Impact factor: 16.971

Review 8.  Vaccination to gain humoral immune memory.

Authors:  Jana Sarkander; Shintaro Hojyo; Koji Tokoyoda
Journal:  Clin Transl Immunology       Date:  2016-12-23

Review 9.  Vaccines for the 21st century.

Authors:  Isabel Delany; Rino Rappuoli; Ennio De Gregorio
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

10.  In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.

Authors:  Daniel Todt; Anett Gisa; Aleksandar Radonic; Andreas Nitsche; Patrick Behrendt; Pothakamuri Venkata Suneetha; Sven Pischke; Birgit Bremer; Richard J P Brown; Michael P Manns; Markus Cornberg; C Thomas Bock; Eike Steinmann; Heiner Wedemeyer
Journal:  Gut       Date:  2016-05-24       Impact factor: 23.059

View more
  5 in total

Review 1.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

2.  Serological diagnosis of Mycoplasma pneumoniae infection by using the mimic epitopes.

Authors:  Wenyuan Shi; Lanhua Zhao; Shengtao Li; Guizhen Xu; Yanhua Zeng
Journal:  World J Microbiol Biotechnol       Date:  2018-05-29       Impact factor: 3.312

3.  An ethanol extract of Lysimachia mauritiana exhibits inhibitory activity against hepatitis E virus genotype 3 replication.

Authors:  Seong Eun Jin; Jung-Eun Kim; Sun Yeou Kim; Bang Ju Park; Yoon-Jae Song
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

4.  B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants.

Authors:  Manojit Bhattacharya; Ashish Ranjan Sharma; Bidyut Mallick; Sang-Soo Lee; Eun-Min Seo; Chiranjib Chakraborty
Journal:  Front Microbiol       Date:  2022-08-12       Impact factor: 6.064

5.  Bioprospecting by Phage Display of Mimetic Peptides of Chlamydia trachomatis for Use in Laboratory Diagnosis.

Authors:  Larissa Silva de Freitas; Maria Alice Freitas Queiroz; Luiz Ricardo Goulart; Luiz Fernando Almeida Machado; Antonio Carlos Rosário Vallinoto; Marluísa de Oliveira Guimarães Ishak; Fabiana de Almeida Araújo Santos; Ricardo Ishak
Journal:  Infect Drug Resist       Date:  2022-08-30       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.